Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder|
- PANSS total score (clinical state)
- Positive Symptoms
- Negative Symptoms
- Depressive Symptoms
- Cognitive Functions
- Social Functioning
- C-Reactive Protein changes
- Lipid Enzyme changes
|Study Start Date:||July 2003|
|Study Completion Date:||July 2007|
|Primary Completion Date:||January 2007 (Final data collection date for primary outcome measure)|
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms and also to improve cognitive functioning. It consists of 15 total study visits over a 28-week period of time, one visit every 2 weeks.
Blood draws will be done once every 4 weeks throughout the study to monitor lipid levels, C-Reactive protein, AST, ALT, and CPK Total. Cognitive testing will be completed at the beginning of the study and at the end of the study. During the study visits, the staff will be monitoring vitals signs (weight, height, blood pressure, pulse, waist/hip ratio), possible side effects, positive and negative symptoms, mood symptoms, and overall functioning.
|United States, Pennsylvania|
|Western Psychiatric Institute & Clinic|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Jaspreet S Brar, MD, MPH||University of Pittsburgh|